AI Article Synopsis
- A study compared the effects of Lurasidone (LUR) and Quetiapine Extended Release (QUE-ER) on treatment discontinuation in patients with bipolar depression over one year, involving 317 participants.
- Although no significant difference in overall discontinuation rates was found between the two medications (p=0.317), adverse events (AEs) were linked to increased discontinuation risk (p<0.0001).
- The main AEs were akathisia for LUR and somnolence for QUE-ER, with each associated with higher discontinuation rates for their respective medications.
Article Abstract
Introduction: Lurasidone (LUR) was compared with quetiapine extended release (QUE-ER) regarding 1-year discontinuation in patients with bipolar depression (n=317).
Methods: This is a retrospective cohort study.
Results: Although the time to all-cause discontinuation was estimated using the Kaplan-Meier survival curve with log-rank tests to compare treatment groups, no difference was found (p=0.317). The Cox proportional hazard model revealed that only the presence of adverse events (AEs) is associated with increased treatment discontinuation (p<0.0001). The most common AEs were akathisia for LUR (17.7%) and somnolence for QUE-ER (34.7%). In other Cox models divided by LUR or QUE-ER, the presence of akathisia or somnolence was associated with increased LUR (p=0.0205) or QUE-ER (p<0.0001) discontinuation, respectively.
Discussion: The acceptability of both antipsychotics to bipolar depression in clinical practice may be similar. However, specific AEs for each antipsychotic (LUR: akathisia and QUE-ER: somnolence) were associated with high treatment discontinuation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2331-2300 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!